AC Immune (ACIU) Projected to Post Quarterly Earnings on Thursday

AC Immune (NASDAQ:ACIU) is expected to announce its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $1.1440 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 12:30 PM ET.

AC Immune Price Performance

Shares of AC Immune stock opened at $3.04 on Wednesday. The firm has a 50 day simple moving average of $3.16 and a 200 day simple moving average of $3.01. AC Immune has a fifty-two week low of $1.43 and a fifty-two week high of $4.00. The firm has a market cap of $305.25 million, a P/E ratio of -3.62 and a beta of 1.64.

Wall Street Analyst Weigh In

Several research firms have recently commented on ACIU. Weiss Ratings reissued a “sell (d-)” rating on shares of AC Immune in a research note on Wednesday, January 21st. Wall Street Zen upgraded AC Immune from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. EFG International AG bought a new position in shares of AC Immune in the 4th quarter worth $41,000. Private Advisor Group LLC acquired a new position in AC Immune in the third quarter valued at about $48,000. Goldman Sachs Group Inc. lifted its stake in AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after buying an additional 5,920 shares during the period. Susquehanna International Group LLP acquired a new position in shares of AC Immune during the 3rd quarter worth about $63,000. Finally, Sei Investments Co. acquired a new position in shares of AC Immune during the 2nd quarter worth about $51,000. Institutional investors and hedge funds own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.